



Curriculum Vitae

Personal information Miguel-Angel Macia

Work experience

1. Employer: Spanish Agency of Medicines and Medical Devices (AEMPS)
 - Start date: 072005
 - End date: 062015
 - Position: Head Risk Assessment Unit_Pharmacoepidemiology and Pharmacovigilance Division
 - Activities: Coordination and oversight of pharmacovigilance Assessment Reports of European procedures Signal evaluation arising from the Spanish Pharmacovigilance System, Assessment reports on drug safety issues to the Spanish Committee on Drug Safety, Spain alternate member of the Pharmacovigilance Risk Assessment Committee. Rapporteurship in the PRAC. Review of Safety Communications from the Spanish Medicines Agency (AEMPS).
 - Country: Spain
2. Employer: Regional Health Service of Castilla-La Mancha
 - Start date: 032004
 - End date: 062005
 - Position: Head and Coordinator of the Rational Use of Drugs Unit
 - Activities: Promotion of the quality of drug prescription in clinical practice: automated prescription tools, therapeutic bulletins. Regional administration of clinical trials and companies sponsored epidemiological studies.
 - Country: Spain
3. Employer: Castilla-La Mancha Regional Authority on public health
 - Start date: 011993
 - End date: 022004
 - Position: Officer in charge of the Pharmacovigilance Regional Center
 - Activities: Management of adverse drug reactions (ADR) case reports: data coding and quality assurance, medical evaluation, communications with healthcare professionals. Identification and assessment of pharmacovigilance signals . Benefit_risk Assessment reports
 - Country: Spain
4. Employer: School of Medicine, Madrid Autonomous University.
 - Start date: 011992
 - End date: 121992
 - Position: Staff member, Pharmacology Department. Clinical pharmacology research unit
 - Activities: Investigator team, healthy volunteers selection and monitoring, drug analysis (HPLC).
 - Country: Spain
5. Employer: La Paz' University Hospital, Autonomous University. Madrid
 - Start date: 041988
 - End date: 121991
 - Position: Residence internship in Clinical pharmacology
 - Activities: Internal Medicine Dept, Medical Emergencies Dept: clinical responsibilities as medical doctor Clinical Pharmacology Dept.: clinical pharmacokinetics analysis and reports, local research ethics committee assessor.
 - Country: Spain
6. Employer: Spanish Agency of Medicines and Medical Devices (AEMPS)
 - Start date: 072015
 - End date:
 - Position: Head of Pharmacoeconomics _ Pharmacoeconomics and Pharmacovigilance Division
 - Activities: Oversight of protocols of non_interventional Post_authorisation studies performed in Spain Perform studies to assess the impact of risk minimization measures undertaken by the AEMPS. Assessment of protocols of Post_authorisation safety studies in EMA _ Pharmacovigilance Risk Assessment Committee (PRAC) procedures. Coordination of BIFAP Program (Spanish Primary Healthcare database for Pharmacoeconomic Research)
 - Country: Spain

Education and training

1. Subject: Carlos III University. Getafe (Madrid)
 - Start date: 092012
 - End date: 102013
 - Qualification: Master in Health Evaluation and Market Access (Pharmaco_economics)
 - Organisation: Clinical Research, Pharmaco_Economic Evaluation, Research in Health Outcomes, Market Access
 - Country: Spain
2. Subject: "La Paz" University Hospital, Autonomous University. Madrid.
 - Start date: 041988
 - End date: 121991
 - Qualification: Medical specialty in Clinical Pharmacology
 - Organisation: _Experimental Pharmacology _Clinical Medicine _Clinical Pharmacokinetics and therapeutic drug monitoring _Pharmacovigilance _Clinical Trials methodology and ethics
 - Country: Spain
3. Subject: School of Medicine. Autonomous University. Madrid
 - Start date: 091980

- End date: 061986
- Qualification: Medical Doctor
- Organisation: Degree in Medicine and Surgery
- Country: Spain

Additional information

Publications

Books (chapters/editor): 5 Communications to congress and scientific meetings: 24 Articles (indexed in Medline): Plueschke, K., Flynn, R., Hedenmalm, K. et al. Prescribing Patterns of Codeine and Alternative Medicines in Children in Europe. *Drug Saf* 45, 1069–1081 (2022). https://doi.org/10.1007/s40264_022_01214_y de Burgos_Gonzalez, A., Bryant, V., Maciá_Martinez, M. A., & Huerta, C. (2021). A strategy for assessment and validation of major bleeding cases in a primary health care database in Spain. *Pharmacoepidemiology and drug safety*, 10.1002/pds.5357. Advance online publication. <https://doi.org/10.1002/pds.5357> Maciá_Martínez M. A., Gil M, Huerta C, et al. Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain. *Pharmacoepidemiol Drug Saf.* 2020;1–10. <https://doi.org/10.1002/pds.5006> Hedenmalm K, Blake K, Donegan K, Macia MA, Gil M, Williams J, Montero D, Candore G, Morales D, Kurz X, Arlett P. A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. *Pharmacoepidemiol Drug Saf.* 2019;28:1086–1096. <https://doi.org/10.1002/pds.4836> de Vries ST, van der Sar MJM, Coleman AM, Escudero Y, Rodríguez Pascual A, Maciá Martínez MA, Cupelli A, Baldelli I, Šipić I, Andrić A, Michan L, Denig P, Mol PGM. Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study. *Drug Safety* 41(6). March 2018 DOI: 10.1007/s40264_018_0643_5 Wisniewski AF, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, Macia_Martinez MA, Manlik K, Quarcoo N, Seabroke S, Slattery J, Southworth H, Thakrar B, Tregunno P, Van Holle L, Kayser M, Norén GN. Good Signal Detection Practices: Evidence from IMI PROTECT. *Drug Saf.* 2016 Jun;39(6):469–90. Maciá_Martínez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AF. An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies. *Drug Saf.* 2016 Jan;39(1):29–43. Maciá Martínez MA. Economic evaluation of the restriction in the use piroxicam in Spain. *Reumatol Clin.* 2015 Nov_Dec;11(6):345–352. Catalá_López F, Martín_Serrano G, Maciá MA, Montero D. Olmesartan for the prevention or delay of diabetic nephropathy: some considerations. *Rev Esp Cardiol (Engl Ed).* 2012 Jul;65(7):678–9; Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population_based cohort study. *Br J Clin Pharmacol.* 2011 Dec;72(6):965–8. Geijo Martínez MP, Maciá Martínez MA, Solera Santos J, Barberá Farré JR, Rodríguez Zapata M, Marcos Sánchez F, Martínez Alfaro E, Cuadra García_Tenorio F, Sanz Moreno J, Moreno Mendaña JM, Beato Pérez JL, Sanz Sanz J; GECMEI. [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral_naive treatment with advanced HIV infection]. *Rev Clin Esp.* 2006 Feb;206(2):67–76. Solera J, Geijo P, Largo J, Rodríguez_Zapata M, Gijón J, Martínez_Alfaro E, Navarro E, Macia MA; Grupo de Estudio de Castilla_la Mancha de Enfermedades Infecciosas. A randomized, double_blind study to assess the optimal duration of doxycycline treatment for human brucellosis. *Clin Infect Dis.* 2004 Dec 15;39(12):1776–82. Carvajal A, Maciá MA, del Pozo JG, de Abajo F. Small risk ratios may have strong public health impact. *BMJ.* 2003 Nov 1;327(7422):1050–1. Maciá MA, Carvajal A, del Pozo JG, Vera E, del Pino A. Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System. *Clin Pharmacol Ther.* 2002 Nov;72(5):596–7. Cuenca Boy R, Ortiz de Apodaca Ruiz MA, Maciá Martínez MA. [Best result of digoxin dosing in the aged by taking into account that both the elimination as well as the volume of distribution of the drug decrease when the kidney function deteriorates]. *An Med Interna.* 2002 Jul;19(7):331–5. Cuenca Boy R, Maciá Martínez MA, López Reneo R, Martín Montero MP. [Predictive capacity of 3 methods for estimating the maintenance dose of digoxin in elderly patients]. *Arch Cardiol Mex.* 2001 Oct_Dec;71(4):306–12. Martínez Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez Martínez PA, Rodríguez Zapata M, Largo J, Sepúlveda MA, Rosa C, Sánchez L, Espinosa A, Mateos F, Blanch JJ. [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group]. *Med Clin (Barc).* 2000 Jul 1;115(5):161–5. Cuenca Boy R, Maciá Martínez MA. [Extrapyramidal toxicity caused by metoclopramide and clobopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]. *Aten Primaria.* 1998 Mar 31;21(5):289–95. Maciá Martínez MA, Cuenca Boy R, Solera Santos J. [Experience in performing a clinical trial not promoted by the pharmaceutical industry]. *Med Clin (Barc).* 1997 Mar 1;108(8):314–5. Maciá MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. *Int J Clin Pharmacol Ther.* 1995 Jun;33(6):333–9. Muñoz_Fernández S, Maciá MA, Pantoja L, Cardenal A, Peña JM, Martín Mola E, Balsa A, Barbado FJ, Vázquez JJ, Gijón Baños J. Osteoarticular infection in intravenous drug abusers: influence of HIV infection and differences with non drug abusers. *Ann Rheum Dis.* 1993 Aug;52(8):570–4.

Projects

EMA/2020/46/TDA/12, Lot 5 Covid Vaccines Effectiveness (CoVE) Effectiveness of heterologous and booster Covid_19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid_19 vaccination regimen : Member of the Scientific Team and Data Access Provider

Memberships

Member: Spanish Society of Clinical Pharmacology

Other Relevant Information